Jaguar Land Rover trains thousands of electric car mechanics
According to the Institute of the Motor Industry, only one in five car mechanics in the UK are currently trained to service EVs
By Shajil KumarMay 30, 2024
JAGUAR LAND ROVER (JLR) is now training thousands of electric car mechanics as skills shortage is forcing drivers to pay more for repair costs, The Telegraph reports.
According to the Institute of the Motor Industry, only one in five car mechanics in the UK are currently trained to service EVs. Hence the garages that have the expertise charge higher fees.
This has also led to higher insurance premiums for EV drivers. Insurance broker Howden claims the average premium for EVs is roughly double when compared with petrol cars.
JLR said it has trained 1,651 mechanics across its 136 garages in the UK, and globally it has trained more than 10,000.
The carmaker is also training around 2,400 factory workers in Britain in EV production methods, as it prepares for the launch of the first all-electric Range Rover later this year.
JLR expects to deliver electrified Range Rover to drivers by 2025. The trials are currently taking place in Sweden’s Arctic territories.
The carmaker plans to electrify its entire lineup by 2030.
The company also plans to manufacture some EV components in-house to strengthen its supply chain. They include making its electric drive units in Wolverhampton and using batteries made in Somerset by sister company Agratas, also part of the Tata industrial empire.
JLR plans to make other components such as inverters, transmissions, battery packs, battery cells, and control modules.
Meanwhile, industry figures showed that car production fell for the second consecutive month in April, as manufacturers continue to prepare for new electric models.
The Society of Motor Manufacturers and Traders said 61,820 cars were built last month, down by 7 per cent compared to a year earlier.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.